- Home
- GNTX vs RYTM Comparison
GNTX vs RYTM Comparison
Compare GNTX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTX
- RYTM
- Stock Information
- Founded
- GNTX 1974
- RYTM 2008
- Country
- GNTX United States
- RYTM United States
- Employees
- GNTX N/A
- RYTM N/A
- Industry
- GNTX Auto Parts:O.E.M.
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- GNTX Consumer Discretionary
- RYTM Health Care
- Exchange
- GNTX Nasdaq
- RYTM Nasdaq
- Market Cap
- GNTX 5.6B
- RYTM 6.4B
- IPO Year
- GNTX N/A
- RYTM 2017
- Fundamental
- Price
- GNTX $26.35
- RYTM $108.05
- Analyst Decision
- GNTX Buy
- RYTM Strong Buy
- Analyst Count
- GNTX 6
- RYTM 13
- Target Price
- GNTX $28.33
- RYTM $110.38
- AVG Volume (30 Days)
- GNTX 2.6M
- RYTM 544.4K
- Earning Date
- GNTX 10-24-2025
- RYTM 11-04-2025
- Dividend Yield
- GNTX 1.83%
- RYTM N/A
- EPS Growth
- GNTX N/A
- RYTM N/A
- EPS
- GNTX 1.77
- RYTM N/A
- Revenue
- GNTX $2,384,794,644.00
- RYTM $156,287,000.00
- Revenue This Year
- GNTX $11.01
- RYTM $46.14
- Revenue Next Year
- GNTX $6.50
- RYTM $63.37
- P/E Ratio
- GNTX $14.79
- RYTM N/A
- Revenue Growth
- GNTX 2.43
- RYTM 53.55
- 52 Week Low
- GNTX $20.28
- RYTM $45.91
- 52 Week High
- GNTX $31.48
- RYTM $113.91
- Technical
- Relative Strength Index (RSI)
- GNTX 40.91
- RYTM 59.05
- Support Level
- GNTX $26.03
- RYTM $105.40
- Resistance Level
- GNTX $26.96
- RYTM $113.56
- Average True Range (ATR)
- GNTX 0.50
- RYTM 4.20
- MACD
- GNTX -0.01
- RYTM 0.52
- Stochastic Oscillator
- GNTX 33.90
- RYTM 65.19
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.